Sign in →

Test Code FINA NAbFeron (IFNB-1) Neutralizing Antibody Test

Reporting Name

NAbFeron (IFN-B) Antibody

Performing Laboratory

Athena Diagnostics

Specimen Type

Serum


Specimen Required


Patient Preparation: Specimen should be collected either before treatment with interferon or more than 24 hours following the most recent dose. Patient should not be on steroid therapy for at least two weeks prior to testing.

Collection Container/Tube: Red top or serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 2 mL serum

Collection Instructions:

1. Within 48 hours of collection, centrifuge and aliquot 2 mL of serum into a plastic vial.

2. Send refrigerate.


Specimen Minimum Volume

Serum: 0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 28 days
  Frozen  180 days
  Ambient  72 hours

Reference Values

<1:20

Day(s) Performed

Monday through Friday

Test Classification

This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. .

CPT Code Information

86382

LOINC Code Information

Test ID Test Order Name Order LOINC Value
FINA NAbFeron (IFN-B) Antibody Not Provided

 

Result ID Test Result Name Result LOINC Value
Z0083 NAbFeron (IFN-B) Antibody Not Provided

Clinical Reference

1. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007;68(13):977-984

2. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010;9(7):740-750

3. Creeke Pl, Farrell RA. Clinical testing for neutralizing antibodies to interferon-ß in multiple sclerosis. Ther Adv Neurol Disord. 2013;6(1):3-17

Report Available

14 to 25 days

Reject Due To

All specimens will be evaluated by the processing and performing laboratories for test suitability.

Method Name

Viral Cytopathic Effect Assay

Secondary ID

91447

Cautions

The present of neutralizing antibodies to interferon beta, especially in persistently high titers, may be associated with reduction in the clinical effectiveness of interferon beta therapy.(1) Although the measurement of Nabs can add to the clinical and imaging information used to assess the efficacy of interferon beta therapy, these results should be interpreted in the context of clinical presentation and medical history.(2,3)

 

Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data.

Clinical Information

Refer to www.athenadiagnostics.com/view-full-catalog